Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Measuring the costs of cancer treatment – what model should we use?

Measuring the costs of cancer treatment – what model should we use? The cost of providing cancer care to an ageing population is growing, and healthcare planners around the world are questioning how they can continue to deliver high‐quality care in an equitable way. There have been calls for radical shifts in cancer policy and better use of cost‐saving technologies along with more transparent regulatory systems (Sullivan et al . ). In this issue of the Journal we feature several papers examining the cost of cancer treatments. Dranitsaris et al . ( ) describe a new method to derive prices for new drugs coming on to the market based on drug performance – in the hope that this will provide better access to new treatments and greater transparency in drug pricing; clearly these methods warrant consideration. See also the accompanying Letter to the Editor from Yusuf Hamied – he has been a tireless campaigner for access to affordable medications, particularly in developing countries. In his letter he highlights some of the inequities that exist (in terms of access to lifesaving treatments) between wealthy and developing countries (Hamied ). van Gils et al . ( ) describe ‘real world’ studies in which effects and costs of treatments are examined in daily http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Cancer Care Wiley

Measuring the costs of cancer treatment – what model should we use?

Weller, D.
European Journal of Cancer Care , Volume 24 (3) – May 1, 2015
Download PDF
3 pages

Loading next page...
 
/lp/wiley/measuring-the-costs-of-cancer-treatment-what-model-should-we-use-JeDArYYtOw

References (19)

Publisher
Wiley
Copyright
Copyright © 2015 John Wiley & Sons Ltd
ISSN
0961-5423
eISSN
1365-2354
DOI
10.1111/ecc.12323
pmid
25876018
Publisher site
See Article on Publisher Site

Abstract

The cost of providing cancer care to an ageing population is growing, and healthcare planners around the world are questioning how they can continue to deliver high‐quality care in an equitable way. There have been calls for radical shifts in cancer policy and better use of cost‐saving technologies along with more transparent regulatory systems (Sullivan et al . ). In this issue of the Journal we feature several papers examining the cost of cancer treatments. Dranitsaris et al . ( ) describe a new method to derive prices for new drugs coming on to the market based on drug performance – in the hope that this will provide better access to new treatments and greater transparency in drug pricing; clearly these methods warrant consideration. See also the accompanying Letter to the Editor from Yusuf Hamied – he has been a tireless campaigner for access to affordable medications, particularly in developing countries. In his letter he highlights some of the inequities that exist (in terms of access to lifesaving treatments) between wealthy and developing countries (Hamied ). van Gils et al . ( ) describe ‘real world’ studies in which effects and costs of treatments are examined in daily

Journal

European Journal of Cancer Care – Wiley

Published: May 1, 2015

There are no references for this article.